Unlocking the Potential of G-Protein-Coupled Receptors in Immune-Mediated Diseases


We are working on medicines* to fulfill unmet needs. We believe that small-molecule therapies targeting G-protein-coupled receptors (GPCRs) have the potential to transform the lives of patients with immune-mediated diseases.


We care more and act differently. This isn’t just a slogan. It’s a commitment to act, born of our persistence. With a pipeline grounded in 2 decades of world-class GPCR discovery research, we are investigating treatments that address unmet needs, designing trials with patients’ lives in mind, and forming partnerships to ensure the development of important medicines.*

Since our development of assays—including Constitutively Activated Receptor Technology (CART), a method of making a single amino acid change to GPCR sequences that causes the GPCRs to favor an active state, and our initial human tissue mapping of GPCR 2 decades ago—we haven’t slowed.1 In the past 2 years alone, this is just a sample of what we’ve accomplished:

We’re developing small-molecule compounds with patient needs in mind. This is what drives us in the development of all of our molecules. We believe our investigational drug etrasimod has shown promise in potentially addressing the needs of patients with immune-mediated diseases. It is a once-daily, oral, selective, sphingosine 1-phosphate receptor modulator that we are evaluating for the treatment of inflammatory bowel disease (ulcerative colitis and Crohn’s disease) as well as eosinophilic esophagitis, atopic dermatitis, and alopecia areata.

We are a company that never stops thinking, caring, or doing . . . until it’s done.

About Arena Pharmaceuticals
Arena Pharmaceuticals is a team with a singular purpose, to deliver important medicines* to patients. The global market is changing rapidly. This is the urgency that drives us to understand the needs of our stakeholders, to identify bold— sometimes disruptive— ideas that will get medicines to patients, and to relentlessly execute until it’s done. Arena. Care More. Act Differently.

To learn more about the science behind Arena, explore our pipeline, and access clinical trials, visit ArenaPharm.com.

*Arena is a clinical stage pharmaceutical company that does not have any medicines or products approved for use by any health authority.
Etrasimod is an investigational drug and is not currently approved for use by any health authority.

1. Arena Pharmaceuticals, Inc. announces multi-receptor CART collaboration with TaiGen Biotechnology Co., Ltd. News release. August 20, 2001. Accessed September 17, 2021. https://invest.arenapharm.com/news-releases/news-release-details/arena-pharmaceuticals-inc-announces-multi-receptor-cart

This article was created in collaboration with the sponsoring company and our sales and marketing team. The editorial team does not contribute.